相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
906
[对肥胖的管理]
Daina Sapovalova1, Chloé Zillweger2, Florence Somers1
1Unité d'éducation thérapeutique du patient, Centre collaborateur OMS, Service de médecine de premier recours, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue medicale suisse
|September 25, 2025
概括
肥胖管理需要在初级保健中采取全面的,个性化的方法,整合患者教育,并发症查和解决体重耻辱问题,以获得有效的长期结果.
科学领域:
- 内部医学 内部医学
- 公共卫生 公共卫生
- 内分泌学 在内分泌学.
背景情况:
- 肥胖是一种复杂的,多因素的,复发性慢性疾病.
- 它是由复杂的生物,心理,社会,环境和遗传影响引起的.
- 有效的管理需要以初级保健为中心的跨学科战略.
研究的目的:
- 概述一个全面的,个性化的,跨学科的方法来管理在初级保健肥胖症.
- 突出成功长期护理的重要支柱.
- 定义初级保健医生的关键作用.
主要方法:
- 审查当前的证据和临床指南,用于肥胖管理.
- 强调以患者为中心的护理,整合治疗性患者教育.
- 包括早期查与肥胖有关的并发症和减轻体重耻辱.
主要成果:
- 治疗性患者教育,早期并发症查和解决体重耻辱至关重要.
- 药物和手术干预是结构化,长期计划中的有效补充.
- 初级保健医生是培养信任和协调护理的核心.
结论:
- 一个整体的,个性化的,跨学科的方法对于管理在初级保健肥胖是必不可少的.
- 长期的成功取决于患者的参与,解决心理社会因素和协调护理.
- 初级保健医生在指导患者通过持续的行为变化和有效管理疾病方面发挥着重要作用.
相关概念视频
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169

